StockData
Avalyn Pharma Inc. logo

Avalyn Pharma Inc. (AVLN) shareholders

AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)

Close on Nov 17, 2026Market cap $1.24BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
99.3%
44M of 44M shares
Institutional holders
92
92 new, 0 sold out
Net institutional buying
44M
In Q2 2026
Insider trades, 12 months
4 buys · 4 sales
Net bought $18.30M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (13.20%)
5,835,25913.20%13G (passive) amendmentJun 30, 2026
Novo Holdings A/S3,883,2898.80%13G (passive)Jun 30, 2026
Simeon George
Joint filing with SR One Capital Management, LLC (7.50%)
3,308,6497.50%13D (active)May 1, 2026
Perceptive Advisors LLC
Joint filing with Joseph Edelman (6.00%), Perceptive Xontogeny Venture Fund II, L.P (5.10%)
2,675,2966.00%13G (passive)Apr 30, 2026
Aaron Cowen
Joint filing with Suvretta Capital Management, LLC (5.60%)
2,503,1095.60%13D (active)May 1, 2026
Genesis VC Partners XV, LLC
Joint filing with Norwest Venture Partners XV, LP (5.10%), NVP Associates, LLC (5.10%) and 2 more
2,268,4045.10%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AVLNValueChange% of portfolio
FMR LLC5,835,25913.16%$192.10MNew0.01%
Novo Holdings A/S3,883,2898.76%$127.84MNew7.42%
Sr One Capital Management, LP3,308,6497.46%$108.92MNew10.48%
Perceptive Advisors LLC2,675,2966.03%$88.07MNew1.32%
Suvretta Capital Management, LLC2,503,1095.65%$82.40MNew1.51%
NVP Associates, LLC2,268,4045.12%$74.68MNew22.75%
Wellington Management Group Llp2,201,9864.97%$72.49MNew0.01%
Price T Rowe Associates Inc /Md/1,735,2313.91%$57.12MNew0.01%
Catalio Capital Management, LP1,675,8303.78%$55.17MNew10.37%
T. Rowe Price Investment Management, Inc.1,602,7453.62%$52.76MNew0.03%
Eventide Asset Management, LLC1,375,4863.10%$45.28MNew0.61%
Bellevue Group AG1,350,0003.05%$44.44MNew0.94%
BlackRock, Inc.977,2642.20%$32.17MNew0.00%
Pivotal bioVenture Partners Investment Advisor LLC966,7922.18%$31.83MNew10.34%
Citadel Advisors LLC959,0982.16%$31.57MNew0.00%
Andera Partners929,8242.10%$30.61MNew14.82%
Jennison Associates LLC812,7491.83%$26.76MNew0.02%
Braidwell LP801,3951.81%$26.38MNew0.98%
Tpg Gp A, LLC773,0691.74%$25.45MNew0.51%
Vanguard Capital Management LLC739,7701.67%$24.35MNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20269244M99.3%92 / 00 / 044M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of AVLNValue% of fundAs of
Fidelity Small Cap Growth Fund1,231,6202.78%$35.46M0.40%Jul 31, 2026
Fidelity Small Cap Growth K6 Fund627,1901.41%$18.06M0.39%Jul 31, 2026
Vanguard Total Stock Market Index Fund534,4401.21%$17.59M0.00%Jun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.415,6100.94%$13.68M0.15%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.396,0690.89%$13.04M0.11%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund385,8050.87%$12.70M0.13%Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.342,1060.77%$11.26M0.11%Jun 30, 2026
iShares Russell 2000 ETF333,8520.75%$10.99M0.01%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.332,4120.75%$10.94M0.07%Jun 30, 2026
PGIM Jennison Health Sciences Fund318,4630.72%$9.17M0.66%May 29, 2026
Fidelity Blue Chip Growth Fund281,3000.63%$8.10M0.01%Jul 31, 2026
Fidelity Growth Company Fund267,6000.60%$7.70M0.01%May 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund217,7770.49%$7.17M0.14%Jun 30, 2026
Vanguard Extended Market Index Fund192,6560.43%$6.34M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund186,9800.42%$5.38M0.02%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lyn BaranowskiChief Executive Officer, Director––May 1, 2026
Adam H. GoldenGeneral Counsel––May 4, 2026
Melissa RhodesChief Operating Officer––May 1, 2026
Douglas R. CarlsonChief Financial Officer––May 1, 2026
Howard LazarusChief Medical Officer––May 1, 2026
Robert J. MeyerDirector––Sep 17, 2026
Heather D. TurnerDirector––May 1, 2026
Jon CongletonDirector––May 1, 2026
Kate HavilandDirector––May 1, 2026
Erin LavelleDirector––May 1, 2026
Jill CarrollDirector1,419,2983.20%May 1, 2026
David Matthew FriedmanDirector––Apr 29, 2026
Llc Fmr10% owner2,056,0814.64%Nov 12, 2026
Holdings A/S Novo10% owner3,883,2898.76%May 5, 2026
Biomedical Innovation Master Investors (Cayman) II L.P. Wellington10% owner1,275,4862.88%May 1, 2026
Sr One Capital Management, Llc10% owner––May 1, 2026
Simeon George10% owner2,263,6085.11%May 1, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Llc Fmr
10% owner
Nov 10, 2026Sale−47,889$30.28$1.45M2,056,081
Llc Fmr
10% owner
Nov 10, 2026Sale−5,565$29.56$164.50K2,103,970
Llc Fmr
10% owner
Nov 9, 2026Sale−1,339$29.75$39.84K2,109,535
Llc Fmr
10% owner
Nov 9, 2026Sale−173,661$29.06$5.05M2,110,874
Holdings A/S Novo
10% owner
May 1, 2026Buy+555,555$18.00$10.00M3,883,289
Holdings A/S Novo
10% owner
May 1, 2026Conversion+3,327,734––3,327,734
Llc Fmr
10% owner
May 1, 2026Conversion+727,585––727,585
Llc Fmr
10% owner
May 1, 2026Conversion+80,291––807,876
Llc Fmr
10% owner
May 1, 2026Conversion+872,868––1,680,744
Llc Fmr
10% owner
May 1, 2026Conversion+225,843––1,906,587
Llc Fmr
10% owner
May 1, 2026Conversion+377,948––2,284,535
Simeon George
10% owner
May 1, 2026Conversion+489,486––844,310
Simeon George
10% owner
May 1, 2026Conversion+1,419,298––1,419,298
Simeon George
10% owner
May 1, 2026Conversion+489,486––1,908,784
Simeon George
10% owner
May 1, 2026Buy+277,778$18.00$5.00M2,186,562
Simeon George
10% owner
May 1, 2026Conversion+354,824––354,824
Simeon George
10% owner
May 1, 2026Buy+277,777$18.00$5.00M1,122,087
Jill Carroll
Director
May 1, 2026Conversion+1,419,298––1,419,298
Jill Carroll
Director
May 1, 2026Conversion+489,486––1,908,784
Jill Carroll
Director
May 1, 2026Buy+277,778$18.00$5.00M2,186,562
Biomedical Innovation Master Investors (Cayman) II L.P. Wellington
10% owner
May 1, 2026Conversion+1,275,486––1,275,486

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.70%
2M shares short
Days to cover
5.3
At 0M shares a day
Change since last report
-2.2%
From 2M shares
Short volume, 20 days
69.4%
Of volume reported to FINRA

Shares sold short, last 6 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avalyn Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,482 shares on Sep 3, 2026 over the last 90 days.

See a number that looks wrong?